MA45920B1 - Inhibiteurs de pyridopyrimidinone cdk2/4/6 - Google Patents

Inhibiteurs de pyridopyrimidinone cdk2/4/6

Info

Publication number
MA45920B1
MA45920B1 MA45920A MA45920A MA45920B1 MA 45920 B1 MA45920 B1 MA 45920B1 MA 45920 A MA45920 A MA 45920A MA 45920 A MA45920 A MA 45920A MA 45920 B1 MA45920 B1 MA 45920B1
Authority
MA
Morocco
Prior art keywords
pyridopyrimidinone
cdk2
inhibitors
compounds
salts
Prior art date
Application number
MA45920A
Other languages
English (en)
Other versions
MA45920A (fr
Inventor
Sacha Ninkovic
Eugene Yuanjin Rui
Douglas Carl Behenna
Asako Nagata
Sajiv Krishnan Nair
Robert Louis Hoffman
Ping Chen
Kevin Daniel Freeman-Cook
Mehran Jalaie
Martha Alicia Ornelas
Cynthia Louise Palmer
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA45920A publication Critical patent/MA45920A/fr
Publication of MA45920B1 publication Critical patent/MA45920B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de formule générale (i), et des sels pharmaceutiquement acceptables de ceux-ci, dans lesquels r1, r2, r2a, r2b, r3, r4, r5a, r5b, r6, r7, r8, r9, p, q et r sont tels que définis dans la description, ainsi que des compositions pharmaceutiques comprenant de tels composés et sels, et sur des procédés d'utilisation de tels composés, sels et compositions pour le traitement d'une croissance cellulaire anormale, y compris le cancer.
MA45920A 2016-08-15 2017-07-31 Inhibiteurs de pyridopyrimidinone cdk2/4/6 MA45920B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662371602P 2016-08-15 2016-08-15
US201762533347P 2017-07-17 2017-07-17
PCT/IB2017/054655 WO2018033815A1 (fr) 2016-08-15 2017-07-31 Inhibiteurs de pyridopyrimidinone cdk2/4/6

Publications (2)

Publication Number Publication Date
MA45920A MA45920A (fr) 2019-06-19
MA45920B1 true MA45920B1 (fr) 2021-08-31

Family

ID=59631834

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45920A MA45920B1 (fr) 2016-08-15 2017-07-31 Inhibiteurs de pyridopyrimidinone cdk2/4/6

Country Status (41)

Country Link
US (4) US10233188B2 (fr)
EP (1) EP3497103B1 (fr)
JP (1) JP6563623B1 (fr)
KR (1) KR102236605B1 (fr)
CN (2) CN114394966A (fr)
AU (1) AU2017311645B2 (fr)
BR (1) BR112019002610A2 (fr)
CA (1) CA2975033C (fr)
CL (1) CL2019000368A1 (fr)
CO (1) CO2019001240A2 (fr)
CR (1) CR20190062A (fr)
CU (1) CU24522B1 (fr)
CY (1) CY1124206T1 (fr)
DK (1) DK3497103T3 (fr)
DO (1) DOP2019000030A (fr)
EC (1) ECSP19011216A (fr)
ES (1) ES2876411T3 (fr)
GE (1) GEP20217234B (fr)
HR (1) HRP20210871T1 (fr)
HU (1) HUE055978T2 (fr)
IL (1) IL264687B (fr)
LT (1) LT3497103T (fr)
MA (1) MA45920B1 (fr)
MD (1) MD3497103T2 (fr)
MX (1) MX2019001849A (fr)
NI (1) NI201900013A (fr)
PE (1) PE20190475A1 (fr)
PH (1) PH12019500329A1 (fr)
PL (1) PL3497103T3 (fr)
PT (1) PT3497103T (fr)
RS (1) RS61934B1 (fr)
RU (1) RU2726115C1 (fr)
SG (1) SG11201900799XA (fr)
SI (1) SI3497103T1 (fr)
SV (1) SV2019005836A (fr)
TN (1) TN2019000039A1 (fr)
TW (1) TWI663169B (fr)
UA (1) UA124804C2 (fr)
UY (1) UY37352A (fr)
WO (1) WO2018033815A1 (fr)
ZA (1) ZA201900716B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2019000039A1 (en) * 2016-08-15 2020-07-15 Pfizer Pyridopyrimdinone cdk2/4/6 inhibitors
JP6952747B2 (ja) * 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
JP2020097562A (ja) * 2018-09-25 2020-06-25 ファイザー・インク ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オンの合成
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
WO2020148635A1 (fr) * 2019-01-17 2020-07-23 Pfizer Inc. Forme cristalline d'un inhibiteur de cdk
WO2020168197A1 (fr) 2019-02-15 2020-08-20 Incyte Corporation Composés de pyrrolo[2,3-d]pyrimidinone en tant qu'inhibiteurs de cdk2
TW202045181A (zh) * 2019-02-15 2020-12-16 美商英塞特公司 細胞週期蛋白依賴性激酶2生物標記物及其用途
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
MX2021012491A (es) * 2019-04-19 2022-01-24 Pfizer Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
WO2020223469A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer
WO2020223558A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Composés aminés tricycliques en tant qu'inhibiteurs de cdk2
EP3976043A1 (fr) * 2019-05-24 2022-04-06 Pfizer Inc. Polythérapies à l'aide d'inhibiteurs cdk
AU2020281535A1 (en) 2019-05-24 2022-01-27 Merck Patent Gmbh Combination therapies using CDK inhibitors
WO2021014360A1 (fr) 2019-07-23 2021-01-28 Pfizer Inc. Formes posologiques à libération modifiée par voie orale
WO2021030537A1 (fr) 2019-08-14 2021-02-18 Incyte Corporation Composés imidazolyl-pyrimidinylamines utilisés comme inhibiteurs de la cdk2
PE20221905A1 (es) * 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
US20240190861A1 (en) * 2019-10-17 2024-06-13 Cisen Pharmaceutical Co., Ltd Aminopyrimidine compound as cdk2/4/6 triple inhibitor
IL293926A (en) 2019-12-17 2022-08-01 Pfizer Antibodies unique to d47, pd-l1 and their uses
US20230135215A1 (en) * 2020-02-28 2023-05-04 Fochon Biosciences, Ltd. Compounds as cdk2/4/6 inhibitors
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
CN113773315A (zh) * 2020-06-10 2021-12-10 无锡佰翱得生物科学有限公司 细胞周期蛋白依赖性激酶2（cdk2）高选择性氘代抑制剂
WO2021254384A1 (fr) * 2020-06-17 2021-12-23 微境生物医药科技(上海)有限公司 Nouveau dérivé de pyrido[2,3-d]pyrimidine-7(8h)-one
WO2022015670A1 (fr) * 2020-07-14 2022-01-20 Nikang Therapeutics, Inc. Dérivés de pyrido[2,3-d]pyrimidin-7(8h)-one utilisés en tant qu'inhibiteurs de kinase 2 dépendant de la cycline
WO2022018667A1 (fr) 2020-07-24 2022-01-27 Pfizer Inc. Polythérapies utilisant des inhibiteurs de cdk2 et de cdc25a
JP7260606B2 (ja) 2020-09-15 2023-04-18 ファイザー・インク 固体形態のｃｄｋ４阻害薬
TW202237585A (zh) 2020-11-27 2022-10-01 瑞士商瑞森製藥公司 Ｃｄｋ抑制劑
WO2022140472A1 (fr) * 2020-12-22 2022-06-30 Nikang Therapeutics, Inc. Composés pour la dégradation de la kinase 2 dépendante des cyclines par l'intermédiaire d'une voie de l'ubiquitine-protéosome
WO2022149057A1 (fr) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Inhibiteurs de cdk
CN117858879A (zh) * 2021-01-15 2024-04-09 南京再明医药有限公司 Cdk2/4/6抑制剂及其制备方法和应用
CA3221997A1 (fr) * 2021-06-09 2022-12-15 Jun Li Compose utile en tant qu'inhibiteur de kinase dependante des cyclines et son utilisation
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
WO2023281413A1 (fr) 2021-07-09 2023-01-12 Pfizer Inc. Méthodes et schémas posologiques comprenant pf-06873600 pour le traitement du cancer
CN116390921A (zh) * 2021-09-29 2023-07-04 中国医药研究开发中心有限公司 具有细胞周期蛋白依赖性激酶抑制活性的杂环化合物及其制备方法和医药用途
CA3238551A1 (fr) * 2021-11-18 2023-05-25 Steven FRUCHTMAN Methodes et compositions pour traitement du cancer
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023111810A1 (fr) 2021-12-14 2023-06-22 Pfizer Inc. Polythérapies et leurs utilisations pour le traitement du cancer
WO2023141522A2 (fr) * 2022-01-21 2023-07-27 Slap Pharmaceuticals Llc Composés multicycliques
WO2023249968A1 (fr) * 2022-06-22 2023-12-28 Nikang Therapeutics, Inc. Composés bifonctionnels contenant des dérivés de pyrido[2,3-djpyrimidin-7(8h)-one pour dégrader la kinase 2 dépendante des cyclines par l'intermédiaire d'une voie ubiquitine-protéasome
US20240174665A1 (en) * 2022-08-19 2024-05-30 Kymera Therapeutics, Inc. Cdk2 inhibitors and uses thereof
WO2024084364A1 (fr) 2022-10-18 2024-04-25 Pfizer Inc. Composés pour le traitement du cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
WO2000035296A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Liberation amelioree d'agents medicamenteux actifs par un enrobage de chewing-gum
CN1237177A (zh) 1996-11-27 1999-12-01 辉瑞大药厂 稠合的二环嘧啶衍生物
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
JP2001509805A (ja) 1997-02-05 2001-07-24 ワーナー−ランバート・コンパニー 細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
KR20020070520A (ko) 2000-01-27 2002-09-09 워너-램버트 캄파니 신경퇴행성 질병의 치료를 위한 피리도피리미디논 유도체
PL358271A1 (en) 2000-03-06 2004-08-09 Warner-Lambert Company 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
ATE305303T1 (de) 2001-02-12 2005-10-15 Hoffmann La Roche 6-substituierte pyridopyrimidine
SI1470124T1 (sl) 2002-01-22 2006-04-30 Warner Lambert Co 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-oni
PA8577501A1 (es) * 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
US6951769B2 (en) 2003-06-04 2005-10-04 Texas Instruments Incorporated Method for stripping sacrificial layer in MEMS assembly
EP1648889B1 (fr) 2003-07-11 2008-10-29 Warner-Lambert Company LLC Sel d'isethionate d'un inhibiteur selectif de la cdk4
EP1718645A1 (fr) 2004-02-18 2006-11-08 Warner-Lambert Company LLC 2-(pyridin-3-ylamino)-pyrido 2,3-d¨pyrimidin-7-ones
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
EA016945B1 (ru) * 2005-10-07 2012-08-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
BRPI0716880A2 (pt) 2006-09-08 2013-10-15 Pfizer Prod Inc Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
SI2074122T1 (sl) * 2006-09-15 2011-10-28 Pfizer Prod Inc Pirido (2,3-d)pirimidinonske spojine in njihova uporaba kot zaviralci PI3
EP1914234A1 (fr) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases
BRPI0810206A2 (pt) * 2007-04-10 2014-10-21 Exelixis Inc Método de tratar câncer
CA2719868A1 (fr) * 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag Pyrimidinyle pyridones inhibiteurs de jnk
WO2010022081A1 (fr) 2008-08-19 2010-02-25 Array Biopharma Inc. Composés de triazolopyridine comme inhibiteurs des kinases pim
JP2012505927A (ja) 2008-10-22 2012-03-08 エフ．ホフマン−ラ ロシュ アーゲー Ｊｎｋのピリミジニルピリドン阻害剤
CN103596951A (zh) * 2011-04-08 2014-02-19 阿弗拉克西斯控股股份有限公司 用于治疗神经系统障碍和癌症的8-乙基-6-(芳基)吡啶并[2,3-d]嘧啶-7(8h)-酮
JP2014513104A (ja) * 2011-04-29 2014-05-29 エクセリクシス， インク． Ｐｉ３ｋ／ｍｔｏｒのピリドピリミジノン阻害剤を用いたリンパ腫の治療方法
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
AR088082A1 (es) 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
MX2014010176A (es) * 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.
SI2958916T1 (sl) 2013-02-21 2018-11-30 Pfizer Inc. Trdne oblike selektivnih zaviralcev CDK4/6
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
US20160304466A1 (en) * 2013-12-04 2016-10-20 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
US9753991B2 (en) 2014-07-31 2017-09-05 Linkedin Corporation Personalized search based on similarity
CZ201589A3 (cs) * 2015-02-11 2016-08-24 Zentiva, K.S. Pevné formy soli Palbociclibu
TN2019000039A1 (en) * 2016-08-15 2020-07-15 Pfizer Pyridopyrimdinone cdk2/4/6 inhibitors

Also Published As

Publication number Publication date
EP3497103A1 (fr) 2019-06-19
EP3497103B1 (fr) 2021-05-05
JP6563623B1 (ja) 2019-08-21
AU2017311645A1 (en) 2019-02-28
US11396512B2 (en) 2022-07-26
LT3497103T (lt) 2021-07-26
CY1124206T1 (el) 2022-05-27
CL2019000368A1 (es) 2019-05-10
SV2019005836A (es) 2019-03-19
IL264687B (en) 2021-04-29
US10800783B2 (en) 2020-10-13
CA2975033A1 (fr) 2018-02-15
RS61934B1 (sr) 2021-07-30
SG11201900799XA (en) 2019-02-27
CA2975033C (fr) 2023-01-24
PE20190475A1 (es) 2019-04-04
CO2019001240A2 (es) 2019-02-19
PT3497103T (pt) 2021-06-17
CU24522B1 (es) 2021-06-08
AU2017311645B2 (en) 2021-05-27
JP2019527722A (ja) 2019-10-03
UY37352A (es) 2018-03-23
MA45920A (fr) 2019-06-19
RU2726115C1 (ru) 2020-07-09
PH12019500329A1 (en) 2019-10-28
TW201819383A (zh) 2018-06-01
GEP20217234B (en) 2021-03-25
MX2019001849A (es) 2019-05-09
CN109803968A (zh) 2019-05-24
US20180044344A1 (en) 2018-02-15
DOP2019000030A (es) 2019-06-30
US20200392142A1 (en) 2020-12-17
KR20190038915A (ko) 2019-04-09
MD3497103T2 (ro) 2021-08-31
US20190135817A1 (en) 2019-05-09
WO2018033815A1 (fr) 2018-02-22
CU20190010A7 (es) 2019-10-04
CN114394966A (zh) 2022-04-26
US10233188B2 (en) 2019-03-19
BR112019002610A2 (pt) 2019-07-02
DK3497103T3 (da) 2021-06-14
TWI663169B (zh) 2019-06-21
TN2019000039A1 (en) 2020-07-15
PL3497103T3 (pl) 2021-10-25
HUE055978T2 (hu) 2022-01-28
ES2876411T3 (es) 2021-11-12
KR102236605B1 (ko) 2021-04-05
NI201900013A (es) 2019-04-08
SI3497103T1 (sl) 2021-07-30
UA124804C2 (uk) 2021-11-24
HRP20210871T1 (hr) 2021-07-09
ZA201900716B (en) 2022-03-30
US20220324872A1 (en) 2022-10-13
CR20190062A (es) 2019-05-22
ECSP19011216A (es) 2019-03-29

Similar Documents

Publication Publication Date Title
MA45920B1 (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA54327B1 (fr) Inhibiteurs de kras g12c
MA47079B1 (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
CU20210065A7 (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria en cdk2
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
PH12018501920A1 (en) Bromodomain inhibitors
MA41051B1 (fr) Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MA38175A1 (fr) Lactames fusionnés à un aryle et hétéroaryle
LTC1934174I2 (lt) Azetinidai kaip MEK inhibitoriai, skirti proliferacinių ligų gydymui
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
MA47301B1 (fr) Inhibiteurs sélectifs de jak1
MA35109B1 (fr) Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
MA31679B1 (fr) Cuclopentanes de pyrimidyle comme inhibiteurs de proteines kinases akt
MA54608B1 (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
EP4249071A3 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
MA35932B1 (fr) Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
MA38009B1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines